Evidence map›Paper›PMID 42369527›Full record

ArticleThe journal of liquid biopsy2026

Breaking news from ESMO 2025: liquid biopsy novelties in gastrointestinal cancer.

Serena Pillozzi, Giulia Petroni, Daniele Lavacchi, Daniele Rossini, Lorenzo Antonuzzo

Abstract readEditorialNews
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of liquid biopsy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Serena PillozziDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
Giulia PetroniDepartment of Experimental Clinical Medicine, University of Florence, Florence, Italy.
Daniele LavacchiOncology Unit, Careggi University Hospital, Florence, Italy.
Daniele RossiniDepartment of Experimental Clinical Medicine, University of Florence, Florence, Italy.
Lorenzo AntonuzzoDepartment of Experimental Clinical Medicine, University of Florence, Florence, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liquid biopsy (LB) has emerged as a minimally invasive approach to characterize tumor biology and support treatment decision-making across gastrointestinal (GI) malignancies. Advances in circulating biomarkers have expanded its potential clinical applications. While colorectal cancer appears closest to clinical implementation, with ctDNA increasingly integrated into adjuvant and metastatic decision-making, applications in other GI tumors remain largely exploratory. Emerging approaches, including cfDNA methylation profiling, multi-omic assays, and circulating protein or metabolite analyses, have shown promising early signals but require prospective validation. This review summarizes key LB findings presented at ESMO 2025, highlighting translational relevance, current limitations, and future directions for clinical integration.

Indexed as

Circulating tumor DNA (ctDNA)Gastrointestinal cancersLiquid biopsyMinimal residual disease (MRD)Personalized medicine

Identifiers

PMID42369527
PMCPMC13309969

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.